Re: Using Medicare Claims to Examine Long-Term Prostate Cancer Risk of Finasteride in the Prostate Cancer Prevention Trial Editorial Comment

被引：0

作者：

Resnick, Matthew J.

机构：

来源：

JOURNAL OF UROLOGY | 2018年 / 200卷 / 04期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：689 / 689

页数：1

共 50 条

[31] Prostate Cancer Incidence Among Finasteride and Alpha-Blocker Users in the Finnish Prostate Cancer Screening Trial Editorial Comment
Kaplan, Steven A.
JOURNAL OF UROLOGY, 2010, 183 (06): : 2238 - 2239
[32] The Prostate Cancer Risk Calculator From the Prostate Cancer Prevention Trial Underestimates the Risk of High Grade Cancer in Contemporary Referral Patients EDITORIAL COMMENT
Eyre, Stephen J.
JOURNAL OF UROLOGY, 2011, 185 (02): : 488 - 488
[33] Reduction in the Risk of Prostate Cancer: Future Directions After the Prostate Cancer Prevention Trial COMMENT
Thompson, Ian M.
UROLOGY, 2010, 75 (03) : 509 - 510
[34] Prediction of prostate cancer for patients receiving finasteride: Results from the prostate cancer prevention trial
Thompson, Ian M.
Ankerst, Donna Pauler
Chi, Chen
Goodman, Phyllis J.
Tangen, Catherine M.
Lippman, Scott M.
Lucia, M. Scott
Parnes, Howard L.
Coltman, Charles A., Jr.
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (21) : 3076 - 3081
[35] More on Long-Term Effects of Finasteride on Prostate Cancer Mortality Reply
Goodman, Phyllis J.
Tangen, Catherine M.
Thompson, Ian M., Jr.
NEW ENGLAND JOURNAL OF MEDICINE, 2019, 380 (20):
[36] Prevention of prostate cancer. Long-term results of the Prostate Cancer Prevention Trial (PCPT) [Prävention des prostatakarzinoms. Langzeitergebnisse des Prostate Cancer Prevention Trial (PCPT)]
Michel M.S.
Nitschmann S.
Von Hardenberg J.
Der Internist, 2014, 55 (8): : 981 - 982
[37] Does the level of prostate cancer risk affect cancer prevention with finasteride?
Thompson, Ian M.
Tangen, Catherine M.
Parnes, Howard L.
Lippman, Scott M.
Coltman, Charles A., Jr.
UROLOGY, 2008, 71 (05) : 854 - 857
[38] Re: Plasma Phospholipid Fatty Acids and Prostate Cancer Risk in the SELECT Trial Editorial Comment
Taneja, Samir S.
JOURNAL OF UROLOGY, 2014, 191 (03): : 658 - 658
[39] Re: Prostate HistoScanning: A Screening Tool for Prostate Cancer? Editorial Comment
Taneja, Samir S.
JOURNAL OF UROLOGY, 2013, 190 (05): : 1763 - 1763
[40] Comparison of the operating characteristics of PSA for prostate cancer detection for finasteride and placebo in the prostate cancer prevention trial
Thompson, IM
Chi, C
Goodman, P
Tangen, CM
Ankerst, DP
Lucia, MS
Coltman, CA
JOURNAL OF UROLOGY, 2006, 175 (04): : 152 - 153

← 1 2 3 4 5 →